Forsta AP Fonden Sells 6,200 Shares of Hologic, Inc. (NASDAQ:HOLX)

Key Points

• Forsta AP Fonden reduced its stake in Hologic, Inc. by 13.7%, selling 6,200 shares, leaving it with a total of 39,200 shares valued at approximately $2.42 million.
• Several other institutional investors have increased their holdings in Hologic, with notable boosts from SG Americas Securities, which raised its stake by 116.6%, and Farther Finance Advisors, which boosted its shares by 22.3%.
• Hologic recently reported a quarterly earnings per share of $1.08, exceeding analyst expectations, along with a 1.2% increase in revenue year-over-year, totaling $1.02 billion.

Forsta AP Fonden decreased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,200 shares of the medical equipment provider's stock after selling 6,200 shares during the period. Forsta AP Fonden's holdings in Hologic were worth $2,421,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC boosted its stake in shares of Hologic by 22.3% in the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after buying an additional 335 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Hologic by 116.6% in the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after buying an additional 5,172 shares during the last quarter. Brevan Howard Capital Management LP boosted its stake in shares of Hologic by 85.5% in the 4th quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock worth $1,401,000 after buying an additional 8,960 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Hologic by 1.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after buying an additional 528 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in shares of Hologic by 4.5% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after buying an additional 767 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

NASDAQ HOLX opened at $67.99 on Tuesday. The firm has a market cap of $15.12 billion, a price-to-earnings ratio of 28.21, a price-to-earnings-growth ratio of 2.47 and a beta of 0.49. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $65.21 and a 200-day moving average price of $62.61. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. The business's quarterly revenue was up 1.2% compared to the same quarter last year. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. UBS Group raised their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and lifted their target price for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Raymond James Financial reiterated an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Stephens lowered their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $77.83.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.